Latigo Biotherapeutics, Inc. (LTGO) Stock Price & Analysis

39 Followers

LTGO Stock Chart & Stats

$13.11$0.18(1.39%)

At close: Nov 13 4:00 PM EST

Day’s Range: $11.75 - $13.22
52-Week Range: $10.24 - $25.93
Previous Close: $12.93
Volume: N/A
Average Volume (3M): 275.81K
Market Cap: $857.25M
Enterprise Value: $706.98M
Total Cash (Recent Filing): $401.24M
Total Debt (Recent Filing): $1.19M
Price to Earnings (P/E): ―
Beta: 0.78
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Latigo Biotherapeutics, Inc. News

Latigo Biotherapeutics, Inc. trading resumes

09:40 EST Latigo Biotherapeutics (LTGO), Inc. trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks

1w agoLTGO

Latigo Biotherapeutics, Inc. trading halted, volatility trading pause

09:30 EST Latigo Biotherapeutics (LTGO), Inc. trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot

1w agoLTGO

Latigo Biotherapeutics, Inc. trading resumes

09:44 EST Latigo Biotherapeutics (LTGO), Inc. trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks

1w agoLTGO

Latigo Biotherapeutics, Inc. trading halted, volatility trading pause

09:34 EST Latigo Biotherapeutics (LTGO), Inc. trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top

1w agoLTGO

Latigo Biotherapeutics says Todd Smith to succeed Nima Farzan as CEO

Latigo Biotherapeutics (LTGO) announced the appointment of Todd Smith as president and CEO, effective immediately. Smith, who has served as an independent director on Latigo’s board since July 2026, succeeds

1w agoLTGO

Latigo Biotherapeutics Reports Third-Quarter Results and Trial Progress

Latigo Biotherapeutics, Inc. ( ($LTGO) ) has shared an announcement. On November 3, 2026, Latigo’s board appointed Todd Smith as president and chief executive officer, replacing Nima Farzan, who left

1w ago8K LTGO

The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’

The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of

2M agoBRVE LTGO

Latigo Biotherapeutics initiated with a Buy at Jefferies

Jefferies initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $50 price target The firm believes LTG-001 will show at least as good efficacy as Suzetrigine in its

2M agoLTGO

Latigo Biotherapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Latigo Biotherapeutics (LTGO) with an Outperform rating and $36 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

2M agoLTGO

Latigo Biotherapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Yatin Suneja initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $50 price target implying 127% upside. The company has two “binary catalysts and second-mover economics”

2M agoLTGO

Latigo Biotherapeutics initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $73 price target Latigo is clinical-stage biotechnology company developing non-opioid pain medicines without addictive potential, the analyst

2M agoLTGO

Salveen Richter Initiates Buy on Latigo for Differentiated Non‑Opioid Pain Platform and Nav1.8 Pipeline with Strong Peak Sales Potential

Latigo Biotherapeutics, Inc. (LTGO) has received a new Buy rating, initiated by Goldman Sachs analyst, Salveen Richter. Salveen Richter has given his Buy rating due to a combination of factors

2M agoLTGO

Latigo Biotherapeutics Completes IPO and Updates Governance

An update from Latigo Biotherapeutics, Inc. ( ($LTGO) ) is now available. On August 10, 2026, Latigo Biotherapeutics, Inc. closed its initial public offering, selling 19,200,000 shares of common stock

3M ago8K LTGO

Opening Day: Biotech names lead week’s IPO activity

Several companies made their market debuts in the past week, highlighted by strong demand for new biopharma listings and a rare secondary only bank offering that drew attention for its

3M agoTP ATTO

LTGO FAQ

What was Latigo Biotherapeutics, Inc.’s price range in the past 12 months?

Latigo Biotherapeutics, Inc. lowest stock price was $10.24 and its highest was $25.93 in the past 12 months.

What is Latigo Biotherapeutics, Inc.’s market cap?

Latigo Biotherapeutics, Inc.’s market cap is $857.25M.

When is Latigo Biotherapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Latigo Biotherapeutics, Inc.’s earnings last quarter?

Latigo Biotherapeutics, Inc. released its earnings results on Nov 05, 2026. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.626 by $0.076.

Is Latigo Biotherapeutics, Inc. overvalued?

According to Wall Street analysts Latigo Biotherapeutics, Inc.’s price is currently Undervalued.

Does Latigo Biotherapeutics, Inc. pay dividends?

Latigo Biotherapeutics, Inc. does not currently pay dividends.

What is Latigo Biotherapeutics, Inc.’s EPS estimate?

Latigo Biotherapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Latigo Biotherapeutics, Inc. have?

Latigo Biotherapeutics, Inc. has 66,299,350 shares outstanding.

What happened to Latigo Biotherapeutics, Inc.’s price movement after its last earnings report?

Latigo Biotherapeutics, Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.626. Following the earnings report the stock price went down -7.336%.

Which hedge fund is a major shareholder of Latigo Biotherapeutics, Inc.?

Currently, no hedge funds are holding shares in LTGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Latigo Biotherapeutics, Inc. Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description